Clinical Trial Update: Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sacituzumab govitecan for advanced esophageal squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING